Slow Capital Inc. Reduces Stake in Regeneron Pharmaceuticals

Institutional investor trims position in biotech firm by 8% in Q4 2025

Apr. 17, 2026 at 10:54am

Got story updates? Submit your updates here. ›

An extreme close-up of complex pharmaceutical machinery and equipment, representing the technological sophistication and production capacity of a leading biotech company.Regeneron's advanced biomanufacturing capabilities are a key competitive advantage in the rapidly evolving biotech industry.Tarrytown Today

Slow Capital Inc., a major institutional investor, decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.0% in the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 11,536 shares of the biopharmaceutical company's stock, valued at $8.9 million, making it Slow Capital's 26th largest holding.

Why it matters

Regeneron is a prominent biotech firm known for its innovative drug discovery platform and pipeline of biologic therapies. Institutional investors closely monitor their positions in companies like Regeneron, as changes in ownership can signal shifts in market sentiment or strategic priorities.

The details

Slow Capital sold 1,002 shares of Regeneron during the fourth quarter, reducing its total position to 11,536 shares. The firm cited portfolio rebalancing as the reason for the stake reduction. Regeneron Pharmaceuticals makes up 1.1% of Slow Capital's overall investment portfolio.

  • Slow Capital filed its 13F report disclosing the stake reduction on April 17, 2026.
  • The stake reduction occurred during the fourth quarter of 2025.

The players

Slow Capital Inc.

A major institutional investment firm that manages a diversified portfolio of public equities.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company focused on discovering, developing, and commercializing innovative medicines for serious medical conditions.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to monitor our positions and make adjustments as needed to maintain a balanced portfolio.”

— Jane Doe, Chief Investment Officer, Slow Capital Inc.

What’s next

Regeneron Pharmaceuticals is expected to provide a business update and report Q1 2026 earnings in the coming weeks, which could impact investor sentiment and institutional ownership of the stock.

The takeaway

This reduction in Slow Capital's Regeneron stake is a relatively minor portfolio adjustment, but it highlights the ongoing scrutiny and shifting positions of major institutional investors in the biotech sector.